Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Study

Eli Lilly's Zepbound shows greater weight loss than Novo Nordisk's Wegovy, with average reduction of 20.2% versus 13.7%.

l 25%

c 63%

r 13%

Which Weight-Loss Drug Is Better: Wegovy or Zepbound?

TIME Magazine

Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial

USA TODAY

Zepbound tops Wegovy for weight loss in Eli Lilly study

Associated Press

Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says

CNN

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

CNBC

This weight loss drug helped people shed more pounds than Wegovy, new trial results show

NBC News

My patients feel healthier on Ozempic. It's not the best answer for weight loss. | Opinion

USA TODAY

Lilly's Zepbound Tops Wegovy for Weight Loss in Trial

Newsmax

Subscribe to unlock this story

We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!

Get Started

Have an account? Sign in

Overview

A summary of the key points of this story verified across multiple sources.

Eli Lilly's latest study revealed Zepbound results in an average weight loss of 20.2% compared to 13.7% for Wegovy, with 47% more weight loss overall. The trial, funded by Lilly and involving 751 participants, confirmed previous findings and may influence the obesity drug market. Zepbound's increased sales and approval as a dual GIP and GLP-1 agonist might enhance its competitive edge, but both drugs are associated with mild gastrointestinal side effects. Further data on health outcomes beyond weight loss is anticipated.

Written by AI using shared reports from

8 articles

Report issue